Malaysian Genomics Resource Centre Share Price

Equities

MGRC

MYQ0155OO000

Healthcare Facilities & Services

End-of-day quote BURSA MALAYSIA 03:30:00 29/04/2024 am IST 5-day change 1st Jan Change
0.405 MYR +1.25% Intraday chart for Malaysian Genomics Resource Centre -3.57% -8.99%

Financials

Sales 2022 28.36M 5.95M 496M Sales 2023 9.57M 2.01M 167M Capitalization 61.06M 12.8M 1.07B
Net income 2022 7M 1.47M 122M Net income 2023 -19M -3.98M -332M EV / Sales 2022 2.85 x
Net cash position 2022 18.89M 3.96M 330M Net cash position 2023 5.39M 1.13M 94.27M EV / Sales 2023 5.81 x
P/E ratio 2022
13.1 x
P/E ratio 2023
-3.77 x
Employees 16
Yield 2022 *
-
Yield 2023
-
Free-Float 34.16%
More Fundamentals * Assessed data
Dynamic Chart
Malaysian Genomics Resource Centre Berhad Announces Aswath A/L Ramakrishnan, Independent and Non Executive Director Was Not Reelected by Shareholders At the Annual General Meeting CI
Malaysian Genomics Resource, DE Cell Forge Strategic Alliance MT
Malaysian Genomics Resource, Universiti Sains Malaysia Tie Up for Genetics Study MT
Malaysian Genomics Resource Centre Berhad Announces Collaboration Agreement with Universiti Sains Malaysia CI
Malaysian Genomics Resource Centre Berhad Announces Redesignation of Encik Muhammad Badri Bin Hussin to Chief Operating Officer from Director CI
Malaysian Genomics Resource Centre Berhad Announces Appointment of Mohammad Hasni Bin Ibrahim as Independent and Non Executive Member of Audit Committee CI
Malaysian Genomics Resource Centre Berhad Announces Resignation of Muhammad Badri Bin Hussin as Independent and Non Executive Member of Audit Committee CI
Malaysian Genomics Resource Centre Berhad Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Malaysian Genomics Resource Centre Berhad Reports Earnings Results for the Eighteen Months Ended December 31, 2023 CI
Malaysian Genomics Resource Centre Berhad Appoints Mohammad Hasni Bin Ibrahim as Independent and Non Executive Director CI
Malaysian Genomics Resource Centre Berhad Appoints Datuk Wira Muhammad Faizal Bin Zainol as Independent and Non Executive Director CI
Malaysian Genomics Resource Centre Berhad Announces Re-Designation of Aswath A/L Ramakrishnan as A Non-Audit and Risk Management Committee Member CI
Malaysian Genomics Resource Centre Berhad Reports Earnings Results for the Third Quarter Ended September 30, 2023 CI
Malaysian Genomics to Deploy AntChain Blockchain Technology MT
Malaysian Genomics Unit, Dynamic Prestige Consultancy to Operate Dialysis Centers MT
More news
1 day+1.25%
1 week-3.57%
Current month-4.71%
1 month-4.71%
3 months-8.99%
6 months-18.18%
Current year-8.99%
More quotes
1 week
0.40
Extreme 0.4
0.42
1 month
0.40
Extreme 0.4
0.44
Current year
0.40
Extreme 0.4
0.47
1 year
0.40
Extreme 0.4
0.61
3 years
0.40
Extreme 0.4
2.72
5 years
0.14
Extreme 0.14
2.72
10 years
0.14
Extreme 0.14
2.72
More quotes
Managers TitleAgeSince
Chief Operating Officer 51 20/23/20
Corporate Secretary 51 -
Members of the board TitleAgeSince
Director/Board Member 38 24/23/24
Director/Board Member 39 10/23/10
Chairman 25 27/21/27
More insiders
Date Price Change Volume
29/24/29 0.405 +1.25% 95,200
26/24/26 0.4 -2.44% 39,200
25/24/25 0.41 -2.38% 335,900
24/24/24 0.42 0.00% 50,200
23/24/23 0.42 0.00% 17,200

End-of-day quote BURSA MALAYSIA, April 29, 2024

More quotes
Malaysian Genomics Resource Centre Berhad is a Malaysia-based company, which is engaged in providing personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. Its services include Genome Sequencing Services, Genome Analysis Services, Genetic Screening Services and Cancer Immunotherapy. Its whole genome sequencing (WGS) is carried out to obtain the sequence of the entire genome from any eukaryotic or prokaryotic organism. This includes plant, animal, microbial, and human genomes. It offers both de novo sequencing and resequencing as part of its WGS service. Its Genome analysis includes services, such as bioinformatics, trait analysis, and trio sequencing. Its Genetic screening includes Dtect, which offers a range of test panels designed to screen for genetic markers in an individual’s deoxyribonucleic acid (DNA). Its Cancer Immunotherapy includes chimeric antigen receptor (CAR) T-Cell immunotherapy.
More about the company

Annual profits - Rate of surprise